Share

Market Wrap

Novalpina secures UK Court injunction to block Ares’ potential sale of Laboratoire XO

Bianca Boorer's avatar
  1. Bianca Boorer
5 min read

On 10 May, the UK High Court granted UK private equity firm Novalpina (now known as NOAL SCSP) acting by its managing general partner Berkeley Research Group (BRG) an injunction to block Ares Management from selling its shares in French pharmaceuticals business Laboratoire XO (LXO) until 20 May. BRG is seeking to restore ownership of the French Healthcare group to Novalpina after Ares took control of the business last week.

According to a report from the Financial Times, Ares refused to extend a change of control waiver under a €150m loan it lent to LXO (€100m drawn). The change of control was triggered by US consultancy firm BRG’s appointment to take over the running of Novalpina’s investments last summer.

Read all our public content for free

We won't spam. You can unsubscribe at any time.

What are you waiting for?

Try it out
  • We're trusted by 9 of the top 10 Investment Banks

Cookies & Privacy

We would like to use cookies to improve our service. Is that ok?